Detalhe da pesquisa
1.
Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy.
J Cell Mol Med
; 26(3): 940-944, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35014164
2.
Synthesis, equilibrium, and biological study of a C-7 glucose boronic acid derivative as a potential candidate for boron neutron capture therapy.
Bioorg Med Chem
; 59: 116659, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35217358
3.
Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy.
Pharm Res
; 36(10): 144, 2019 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392417
4.
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
Br J Haematol
; 173(1): 70-81, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26729247
5.
A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma.
Pharm Res
; 33(10): 2530-9, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27401411
6.
The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.
Lab Invest
; 94(8): 881-92, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24955893
7.
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Br J Haematol
; 165(1): 89-101, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24405121
8.
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Haematologica
; 104(7): e310-e313, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30655367
9.
Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis.
Arthritis Rheum
; 64(9): 2856-67, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22488178
10.
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy.
J Immunother Cancer
; 10(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35428704
11.
Effectiveness of Soluble CTLA-4-Fc in the Inhibition of Bone Marrow T-Cell Activation in Context of Indoleamine 2.3-Dioxygenase (IDO) and CD4+Foxp3+ Treg Induction.
J Inflamm Res
; 15: 6813-6829, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36578517
12.
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.
Cell Death Dis
; 13(11): 969, 2022 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400754
13.
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Blood Cancer J
; 12(7): 110, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853853
14.
Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.
Haematologica
; 101(7): e307-11, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27081175
15.
CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies.
Leuk Res Rep
; 16: 100268, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34584838
16.
Targeting E-selectin to Tackle Cancer Using Uproleselan.
Cancers (Basel)
; 13(2)2021 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33477563
17.
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.
Leukemia
; 35(8): 2346-2357, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33479469
18.
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.
Sci Rep
; 11(1): 19343, 2021 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588522
19.
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia.
Oncotarget
; 12(19): 1878-1885, 2021 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34548905
20.
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
Leuk Lymphoma
; 62(10): 2457-2465, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33993837